A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blinded, double-dummy, active-controlled, randomized, Phase III
clinical trial to evaluate the efficacy and safety of DA-6034 and to demonstrate the
non-inferiority of DA-6034 compared with Rebamipide in patients with acute or chronic
gastritis. Subjects will receive 45mg, 90mg of DA-6034 and 300mg of Rebamipide, two tablets,
three times a day for two weeks.